このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Khiron Life Sciences バランスシートの健全性

財務の健全性基準チェック /36

Khiron Life Sciencesの総株主資本はCA$27.1M 、総負債はCA$816.0Kで、負債比率は3%となります。総資産と総負債はそれぞれCA$38.5MとCA$11.3Mです。

主要情報

3.0%

負債資本比率

CA$816.00k

負債

インタレスト・カバレッジ・レシオ	n/a
現金	CA$1.94m
エクイティ	CA$27.10m
負債合計	CA$11.35m
総資産	CA$38.45m

財務の健全性に関する最新情報

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

May 03

Recent updates

Khiron Life Sciences Corp. (CVE:KHRN) Stock's 47% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 17

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Khiron Life Sciences Corp.'s (CVE:KHRN) CEO For Now

Jun 24

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

May 03

What Type Of Returns Would Khiron Life Sciences'(CVE:KHRN) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Feb 06

財務状況分析

短期負債: KHRNの短期資産 ( CA$18.3M ) が短期負債 ( CA$9.1M ) を超えています。

長期負債: KHRNの短期資産 ( CA$18.3M ) が長期負債 ( CA$2.3M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: KHRN総負債よりも多くの現金を保有しています。

負債の削減: KHRNの負債対資本比率が過去 5 年間で減少したかどうかを判断するにはデータが不十分です。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: 現在のフリーキャッシュフローに基づいて、 KHRNに十分なキャッシュランウェイがあるかどうかを判断するにはデータが不十分です。

キャッシュランウェイの予測: KHRNのフリーキャッシュフローが過去のレートに基づいて増加または減少し続ける場合、十分なキャッシュランウェイがあるかどうかを判断するためのデータが不十分です。

Khiron Life Sciences バランスシートの健全性

財務の健全性 基準チェック /36

主要情報

財務の健全性に関する最新情報

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

Recent updates

Insufficient new directors

Khiron Life Sciences Corp. (CVE:KHRN) Stock's 47% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Khiron Life Sciences Corp. Announces Full Reimbursement by the NHS of Costs Associated to Cannabis-Based Medication and Clinic Fees for A Patient Enrolled in Zerenia Clinics UK

Third quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.019 loss in 3Q 2021)

Khiron Life Sciences Corp. to Report Q3, 2022 Results on Nov 30, 2022

Price target decreased to CA$0.30

Khiron Launches New Cannabis Products in Europe Including Stellar Genetics from California

Second quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.032 loss in 2Q 2021)

Khiron Life Sciences Corp. to Report Q2, 2022 Results on Aug 29, 2022

Khiron Life Sciences Corp. Announces CFO Changes

Khiron Life Sciences Corp. Announces Resignation of Deborah Rosati from the Board of Directors

Chairman of the Board recently bought CA$150k worth of stock

Khiron Life Sciences Corp. has completed a Composite Units Offering in the amount of CAD 4.01 million.

First quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.036 loss in 1Q 2021)

Khiron Life Sciences Corp. (TSXV:KHRN) entered into an agreement to acquire Pharmadrug Production GmbH from Pharmadrug Inc. (CNSX:PHRX) for $1.82 Million.

Khiron Life Sciences Corp. to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings released: EPS: CA$0.20 (vs CA$0.20 loss in FY 2020)

Price target decreased to CA$0.87

Khiron Life Sciences Corp., Annual General Meeting, Jun 23, 2022

Khiron Life Sciences Corp. Publishes Clinical Study on the Effectiveness of its Products at Controlling Chronic Pain

No longer forecast to breakeven

Khiron Life Sciences Corp. (TSXV:KHRN) acquired Mcs Clinics Limited for 0.3 million.

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Khiron Life Sciences Corp. Presents Its First Research Study with 1,400 Patients

Second quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.049 loss in 2Q 2020)

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Khiron Life Sciences Corp.'s (CVE:KHRN) CEO For Now

Insider recently sold CA$78k worth of stock

First quarter 2021 earnings released: CA$0.036 loss per share (vs CA$0.079 loss in 1Q 2020)

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

Full year 2020 earnings released: CA$0.20 loss per share (vs CA$0.36 loss in FY 2019)

New 90-day high: CA$0.74

New 90-day high: CA$0.59

What Type Of Returns Would Khiron Life Sciences'(CVE:KHRN) Shareholders Have Earned If They Purchased Their SharesYear Ago?

New 90-day low: CA$0.36

Khiron Life Sciences Corp.'s Medical Cannabis Products Now Qualify for National Insurance Coverage in Colombia

Earnings beat expectations, revenue disappoints

Khiron Life Sciences Corp. Appoints Juan Carlos Echeverry to its Board of Directors

Third quarter 2020 earnings released: CA$0.057 loss per share

Khiron Life Sciences Corp. to Report Q3, 2020 Results on Dec 01, 2020

Khiron Life Sciences Corp. has completed a Composite Units Offering in the amount of CAD 12.6 million.

Earnings beat expectations, revenue disappoints

Second quarter 2020 earnings released: CA$0.049 loss per share

New 90-day low: CA$0.40

Khiron Life Sciences Corp. Announces Changes in Chief Financial Officer

New 90-day low: CA$0.45

Price target raised to CA$1.60

Earnings released

New 90-day low - CA$0.47

Khiron Life Sciences Corp. to Report Q2, 2020 Results on Aug 24, 2020

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

キャッシュ・ランウェイ分析

健全な企業の発掘

財務の健全性基準チェック /36